194 related articles for article (PubMed ID: 37865722)
21. Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Antonarakis ES; Tierno M; Fisher V; Tukachinsky H; Alexander S; Hamdani O; Hiemenz MC; Huang RSP; Oxnard GR; Graf RP
Prostate; 2022 May; 82(7):867-875. PubMed ID: 35286728
[TBL] [Abstract][Full Text] [Related]
22. Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care.
Hedtke M; Pessoa Rejas R; Froelich MF; Ast V; Duda A; Mirbach L; Costina V; Martens UM; Hofheinz RD; Neumaier M; Haselmann V
Mol Oncol; 2022 May; 16(10):2042-2056. PubMed ID: 34873826
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
24. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
26. Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.
Boniface CT; Spellman PT
Pathol Oncol Res; 2022; 28():1610103. PubMed ID: 35665409
[TBL] [Abstract][Full Text] [Related]
27. Applications of Liquid Biopsy for Surgical Patients With Cancer: A Review.
Mahuron KM; Fong Y
JAMA Surg; 2024 Jan; 159(1):96-103. PubMed ID: 37910091
[TBL] [Abstract][Full Text] [Related]
28. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
Scilla KA; Rolfo C
Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
[TBL] [Abstract][Full Text] [Related]
29. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
31. Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring.
Hallermayr A; Benet-Pagès A; Steinke-Lange V; Mansmann U; Rentsch M; Holinski-Feder E; Pickl JMA
Clin Chem; 2021 Nov; 67(11):1483-1491. PubMed ID: 34392332
[TBL] [Abstract][Full Text] [Related]
32. Liquid Biopsy in Solid Malignancy.
Scarlotta M; Simsek C; Kim AK
Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
[TBL] [Abstract][Full Text] [Related]
33. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
Lyu X; Tsui YM; Ho DW; Ng IO
Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
[TBL] [Abstract][Full Text] [Related]
34. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
35. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang M; Forbes ME; Bitting RL; O'Neill SS; Chou PC; Topaloglu U; Miller LD; Hawkins GA; Grant SC; DeYoung BR; Petty WJ; Chen K; Pasche BC; Zhang W
Ann Oncol; 2018 Feb; 29(2):311-323. PubMed ID: 29216340
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor DNA and liquid biopsy in oncology.
Cescon DW; Bratman SV; Chan SM; Siu LL
Nat Cancer; 2020 Mar; 1(3):276-290. PubMed ID: 35122035
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
Ranghiero A; Frascarelli C; Cursano G; Pescia C; Ivanova M; Vacirca D; Rappa A; Taormina SV; Barberis M; Fusco N; Rocco EG; Venetis K
Cytopathology; 2023 Nov; 34(6):519-529. PubMed ID: 37640801
[TBL] [Abstract][Full Text] [Related]
40. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
